These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24840727)

  • 21. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
    Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
    Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
    [No Abstract]   [Full Text] [Related]  

  • 22. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
    Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
    Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.
    Law LY
    J Clin Oncol; 2012 Sep; 30(27):e271-3. PubMed ID: 22851567
    [No Abstract]   [Full Text] [Related]  

  • 24. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
    Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
    J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
    [No Abstract]   [Full Text] [Related]  

  • 25. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highlights of topic "new trends on pathology of cholangiocarcinoma".
    Nakanuma Y
    J Hepatobiliary Pancreat Sci; 2014 Jul; 21(7):439-40. PubMed ID: 24942377
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression.
    Li Y; Hu M; Li L; Liu S; He T; Cheng C; Xu M; Yin X
    Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101525. PubMed ID: 32921589
    [No Abstract]   [Full Text] [Related]  

  • 28. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
    Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
    Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
    Borger DR; Zhu AX
    Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
    [No Abstract]   [Full Text] [Related]  

  • 31. Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.
    Lim M; Lynch PT; Bai X; Hsiehchen D
    JCO Precis Oncol; 2023 Jan; 7():e2200340. PubMed ID: 36634295
    [No Abstract]   [Full Text] [Related]  

  • 32. Allelotype analysis of intrahepatic cholangiocarcinoma.
    Kang YK; Kim YI; Kim WH
    Mod Pathol; 2000 Jun; 13(6):627-31. PubMed ID: 10874666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platinum Sensitivity in
    Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
    Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
    Khoury R; Chahine C; Ibrahim R; Khalife N; Saleh M; Saleh K
    Future Oncol; 2023 Jun; 19(17):1161-1163. PubMed ID: 37293779
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical pathology of cholangiocarcinoma (intrahepatic bile duct cancer)].
    Yamamoto M
    Nihon Geka Hokan; 1995 Nov; 64(6):129-30. PubMed ID: 8913088
    [No Abstract]   [Full Text] [Related]  

  • 36. Genetic and molecular abnormalities in cholangiocarcinogenesis.
    Hassid VJ; Orlando FA; Awad ZT; Tan D; Khoury T; Ahmed BH; Alrawi SJ
    Anticancer Res; 2009 Apr; 29(4):1151-6. PubMed ID: 19414358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.
    Lee H; Wang K; Johnson A; Jones DM; Ali SM; Elvin JA; Yelensky R; Lipson D; Miller VA; Stephens PJ; Javle M; Ross JS
    J Clin Pathol; 2016 May; 69(5):403-8. PubMed ID: 26500333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
    Sipra QUAR; Shroff R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):281-284. PubMed ID: 33228417
    [No Abstract]   [Full Text] [Related]  

  • 39. Adrenal metastasis from intrahepatic cholangiocarcinoma.
    Pandey D; Lee KH; Wong SY; Tan KC
    Liver Int; 2007 Sep; 27(7):1016. PubMed ID: 17696942
    [No Abstract]   [Full Text] [Related]  

  • 40. Intrahepatic cholangiocarcinoma showing mixed differentiation: a case report.
    Shimonishi T; Sugawara H; Miyazaki K; Nakanuma Y
    Histopathology; 1998 Nov; 33(5):488-90. PubMed ID: 9839179
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.